[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Liquidia Corp (LQDA)

Liquidia Corp (LQDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,510,868
  • Shares Outstanding, K 88,928
  • Annual Sales, $ 158,320 K
  • Annual Income, $ -68,920 K
  • EBIT $ 46 M
  • EBITDA $ 47 M
  • 60-Month Beta 0.41
  • Price/Sales 34.70
  • Price/Cash Flow N/A
  • Price/Book 50.57

Options Overview Details

View History
  • Implied Volatility 73.71% (+0.66%)
  • Historical Volatility 76.66%
  • IV Percentile 6%
  • IV Rank 5.99%
  • IV High 185.25% on 10/31/25
  • IV Low 66.60% on 06/23/25
  • Expected Move (DTE 7) 3.96 (6.44%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 5,155
  • Volume Avg (30-Day) 10,343
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 154,068
  • Open Int (30-Day) 155,662
  • Expected Range 57.56 to 65.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.71
  • Number of Estimates 4
  • High Estimate $0.86
  • Low Estimate $0.57
  • Prior Year $-0.49
  • Growth Rate Est. (year over year) +244.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.02 +69.29%
on 04/24/26
62.30 -2.12%
on 05/21/26
+23.92 (+64.54%)
since 04/22/26
3-Month
29.12 +109.44%
on 02/26/26
62.30 -2.12%
on 05/21/26
+27.39 (+81.54%)
since 02/20/26
52-Week
11.85 +414.60%
on 07/01/25
62.30 -2.12%
on 05/21/26
+45.42 (+291.90%)
since 05/22/25

Most Recent Stories

More News
Liquidia Q1 Earnings Call Highlights

Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and pulmonary...

LQDA : 60.98 (-1.60%)
Liquidia Corporation Reports First Quarter 2026 Financial Results

YUTREPIA ® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients...

LQDA : 60.98 (-1.60%)
Liquidia: The Market Has Already Priced In What Tomorrow's Report Will Actually Say

Barchart Research What to Expect from LQDA Earnings LQDA Generated May 8, 2026 Current Price $42.30 EPS Estimate $$0.34 Consensus Rating Strong Buy Average Move 4.26% Liquidia: The Market Has Already Priced...

LQDA : 60.98 (-1.60%)
Liquidia: The Market Has Already Priced In What Tomorrow's Report Will Actually Say

Barchart Research What to Expect from LQDA Earnings LQDA Generated May 8, 2026 Current Price $42.30 EPS Estimate $$0.34 Consensus Rating Strong Buy Average Move 4.26% Liquidia: The Market Has Already Priced...

LQDA : 60.98 (-1.60%)
Liquidia: The Market Has Already Priced In What Tomorrow's Report Will Actually Say

Barchart Research What to Expect from LQDA Earnings LQDA Generated May 8, 2026 Current Price $42.30 EPS Estimate $$0.34 Consensus Rating Strong Buy Average Move 4.26% Liquidia: The Market Has Already Priced...

LQDA : 60.98 (-1.60%)
Liquidia Corporation to Participate in Upcoming Investor Conferences

MORRISVILLE, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging...

LQDA : 60.98 (-1.60%)
Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026

MORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging...

LQDA : 60.98 (-1.60%)
Liquidia Corporation to Participate in Upcoming Investor Conferences

MORRISVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging...

LQDA : 60.98 (-1.60%)
Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Achieved YUTREPIA ® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter More than 3,600 unique prescriptions received and 2,900 patients treated to date...

LQDA : 60.98 (-1.60%)
Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026

MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases,...

LQDA : 60.98 (-1.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 80%. The market has dropped from extreme overbought territory, indicating a possible trend reversal.

See More Share

Business Summary

Liquidia Corporation is a biopharmaceutical company. It develops, manufactures and commercializes products for unmet patient needs principally in the United States. Liquidia Corporation, formerly known as LIQUIDIA TECHNL, is based in Morrisville, North Carolina.

See More

Key Turning Points

3rd Resistance Point 65.21
2nd Resistance Point 63.76
1st Resistance Point 62.86
Last Price 60.98
1st Support Level 60.51
2nd Support Level 59.06
3rd Support Level 58.16

See More

52-Week High 62.30
Last Price 60.98
Fibonacci 61.8% 43.03
Fibonacci 50% 37.08
Fibonacci 38.2% 31.12
52-Week Low 11.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.